Journal of Ethnopharmacology
Volume 164, 22 April 2015, Pages 75-77

Research Paper

The effectiveness and safety of a danshen-containing Chinese herbal medicine for diabetic retinopathy: A randomized, double-blind, placebo-controlled multicenter clinical trial

Fengmei Lian [1], Lie Wu [1], Jiaxing Tian [1], Ming Jin, Shuiping Zhou, Min Zhao, Lijuan Wei, Yanlin Zheng, Yuliang Wang, Mingchong Zhong, Wei Qin, Zhifeng Wu, Chun-Su Yuan, Xiaolin Tong

Show more

Add to Mendeley | Share | Cite

https://doi.org/10.1016/j.jep.2015.01.048 | Get rights and content

Abstract

Ethnopharmacological relevance

Salvia miltiorrhiza (Danshen in Chinese) is a common traditional Chinese herbal medicine often used to treating many medical conditions. The Compound Danshen Dripping Pill (CDDP) is a danshen-containing Chinese herbal product for the treatment of cardiovascular diseases. However, to date, no controlled clinical studies have been conducted to evaluate the effects of CDDP on diabetic retinopathy (DR).

Aim of the study

The present large-scale clinical trial was designed to assess the effectiveness and safety of CDDP in treating patients with non-proliferative diabetic retinopathy (NPDR).

Materials and methods

223 NPDR patients were enrolled in this controlled trial. Subjects received oral study medications three times daily for 24 weeks. The four groups were placebo, low-dose (270 mg/, mid-dose (540 mg) and high dose (810 mg herbal powder). Primary endpoints were changes in fluorescence fundus angiography (FFA) and fundoscopic examination parameters.

Results and discussion

At 24 weeks, for the FFA, the percent of "Excellent" and "Effective" in the high-dose and mid-dose CDDP groups was 74% and 77%, respectively, very significantly higher than 28% in the placebo group (P<0.001). For fundoscopic examination, the percent of "Excellent" and "Effective" in the high-dose and mid-dose CDDP groups was 42% and 59%, respectively, very significantly higher than 11% in the placebo group (P<0.001). No adverse events with clinical significance were observed.

Conclusions

DR is a severe microvascular complication of diabetes and a major cause of adult blindness worldwide. Our clinical trial data demonstrated the therapeutic value and safety of a danshen-containing Chinese herbal medicine in patients with diabetic retinopathy.

Graphical abstract

In this controlled clinical trial, we observed the effectiveness and safety of a Danshen-containing Chinese herbal medicine in treating patients with diabetic retinopathy. The FFA improved very significantly after 24-week treatment.



Download: Download high-res image (106KB)
Download: Download full-size image

Introduction

Diabetic retinopathy (DR), a severe microvascular complication of diabetes (Congdon et al., 2003), is a major cause of adult blindness worldwide. The prevalence of DR in China for individuals over 60 years of age is approximately 16%, and its incidence is 8.38/1000 person-years (Li and Wang, 2013). Treatment of DR includes medical management to control blood sugar, blood pressure and serum lipids, ocular management, and adjunctive pharmacologic therapies (Schwartz and Flynn, 2007, Simó and Hernández, 2009, ACCORD Study Group, ACCORD Eye Study Group, 2010). However, these approaches for DR management have limitations including invasive procedures and side effects of drug therapy (Schwartz and Flynn, 2007, Simó and Hernández, 2009, Feng et al., 2014). To date, there are no measures to effectively control the progression of DR. Thus, there is a strong motivation for exploring alternative strategies, including the use of Chinese herbal medicines, in DR therapeutics.

Salvia miltiorrhiza (Danshen in Chinese) is a very commonly used traditional Chinese herbal medicine. Compound Danshen Dripping Pill (CDDP) is a Chinese herbal medicine product used for the treatment of cardiovascular diseases (Chu et al., 2011). It contains the extract from danshen (*Salvia miltiorrhiza*), notoginseng (*Panax notoginseng*; or Sanchi in Chinese), and borneol. These three traditional Chinese medicines have been used for over a thousand years to treat many medical conditions. The CDDP promotes blood circulation and alleviates pain (Chu et al., 2011). Based on the theory of traditional Chinese medicine (TCM), the pathogenesis of DR is due to blood stasis that damages collateral vessels in the eye (Duan et al., 2011). Published animal experiments using different animal models and clinical trials in DR patients have demonstrated that CDDP can improve the symptoms of DR (Zhou et al., 2002, Zhou et al., 2006, Qi et al., 2007, Yang et al., 2013). In addition, CDDP has been studied in different body systems with a good safety record (Xu et al., 2014, Yang et al., 2014). However, to date, no controlled clinical trial has been conducted to evaluate the effects of CDDP on DR.

In the present study, a randomized, double-blind, placebo-controlled, dose-ranging and multicenter clinical trial was conducted. We recruited glycemic-controlled DR patients with non-proliferative diabetic retinopathy (NPDR). These subjects were randomly assigned into four groups, and they received either placebo or three different doses of CDDP to explore the optimal therapeutic dose. The primary endpoints were changes in fluorescence fundus angiography (FFA) and fundoscopic examination parameters after 24 weeks of CDDP treatment. In addition, corrected visual acuity, intraocular pressure, glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) were obtained in these subjects. The safety profile of the CDDP in the study subjects was also collected.

Section snippets

Study subjects

The research protocol was approved by the local Medical Ethics Commission in China, and was implemented in accordance with the provisions of the Declaration of Helsinki.

The inclusion criteria were as follows: (1) Subjects were 30–70 years old. (2) Subjects were diagnosed with NPDR (American Association of Ophthalmology, 2006). (3) Subjects were on a stable oral hypoglycemic treatment for at least three months. (4) Subjects signed written informed consent.

Exclusion criteria were as follows: (1) ...

Results

From the 10 clinical research centers, 223 subjects who met the inclusion criteria and exclusion criteria were enrolled in the study. The mean age of these subjects was 59.3 years old, and among them 41.7% were male subjects. The average duration of NPDR in these patients was 29.7 months. There were no significant differences in the baseline variables of the four groups. The clinical database makes it the most common cause of blindness among non-elderly adults. Since Western medicine has limitations in controlling diabetes and its complications, alternative strategies, ...

Discussion

Diabetes is a significant metabolic disorder that endangers public health. DR is one of the most common complications of diabetes. With DR, the growth of friable and poor-quality new blood vessels in the retina as well as macular edema can eventually lead to severe vision loss or blindness. The retinal damage makes it the most common cause of blindness among non-elderly adults. Since Western medicine has limitations in controlling diabetes and its complications, alternative strategies, ...

Acknowledgments

The efforts of many institutions and scholars made the execution of this project possible. We sincerely thank all the individuals and their affiliated institutions that contributed to this project. We also would like to thank the Tasly Pharmaceutical Group Co., Tianjin, China for providing the Compound Danshen Dripping Pill (CDDP) and placebo pills. This work was supported in part by the National Basic Research Program of China (973 Program, No. 2010CB530600) ...

References (30)

Y. Chu et al.
The effect of compound dripping pills, a Chinese herb medicine, on the pharmacokinetics and pharmacodynamics of warfarin in rats
Journal of Ethnopharmacology (2011)

X.L. Tong et al.
Clinical observations on the dose–effect relationship of Gegen qin lian decoction on 54 out-patients with type 2 diabetes
Journal of Traditional Chinese Medicine (2011)

ACCORD Study Group, ACCORD Eye Study Group
Effects of medical therapies on retinopathy progression in type 2 diabetes
New England Journal of Medicine (2010)

American Association of Ophthalmology
Preferred Practice Pattern
(2006)

M. Brownlee
The pathobiology of diabetic complications: a unifying mechanism
Diabetes (2005)

E.Y. Chew et al.
Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus
Archives of Ophthalmology (1995)

N.G. Congdon et al.
Important causes of visual impairment in the world today
Journal of American Medical Association (2003)

J.G. Duan et al.
Standard of TCM diagnosis and treatment of diabetic retinal lesions
World Journal of Integrated Traditional and Western Medicine (2011)

Early Treatment Diabetic Retinopathy Study Research Group
Effects of aspirin treatment on diabetic retinopathy
Ophthalmology (1991)

L. Feng et al.
Clinical efficacy of aconitum-containing traditional Chinese medicine for diabetic peripheral neuropathic pain
American Journal of Chinese Medicine (2014)

View more references

Cited by (63)

The Yin and Yang of traditional Chinese and Western medicine
2021, Medicinal Research Reviews

Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)
2021, Chinese Journal of Endocrinology and Metabolism

Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: A systematic review and meta-analysis
2019, Diabetes, Obesity and Metabolism

Notoginsenoside R1 ameliorates diabetic retinopathy through PINK1-dependent activation of mitophagy
2019, Cells

NF-κβ: A potential target in the management of vascular complications of diabetes
2017, Frontiers in Pharmacology

Chinese herbal drugs for the treatment of diabetic retinopathy
2017, Journal of Pharmacy and Pharmacology

View all citing articles on Scopus

[1] Fengmei Lian, Lie Wu and Jiaxing Tian are the co-first authors in this work.

View full text